Cytokine and chemokine profiles in the sera of COVID-19 patients with different stage of severity.

COVID-19 Chemokine Cytokine Cytokine storm Disease severity SARS-CoV-2

Journal

Cytokine
ISSN: 1096-0023
Titre abrégé: Cytokine
Pays: England
ID NLM: 9005353

Informations de publication

Date de publication:
22 May 2024
Historique:
received: 11 12 2023
revised: 08 05 2024
accepted: 14 05 2024
medline: 24 5 2024
pubmed: 24 5 2024
entrez: 23 5 2024
Statut: aheadofprint

Résumé

COVID-19 is a viral infection that disturbs the host's immune system and causes an overproduction of cytokines leading to a cytokine storm. The present study aimed to evaluate the serum levels of 27 protein biomarkers to determine their association with COVID-19 disease severity. The serum levels of 89 patients with different degrees of COVID-19 disease severity [asymptomatic (n = 14), moderate (n = 14), severe (n = 30), and critical (n = 31)] and 14 healthy individuals were tested for a panel of 27 cytokines and chemokines using Luminex assay (27 Bio‑Plex Pro Human Cytokine, Bio-rad™). IL-12, IL-2 and IL-13, as well as IL-17 and GM-CSF were clearly undetectable in asymptomatic patients. IL-8 levels were higher in asymptomatic compared with other groups. Very high levels of IL-6, IL-10 and the chemokines MIP-1α, MCP-1 and IP10 were associated with disease progression, while IL-4 tends to decrease with disease severity. Our study provides more evidence that excessive cytokine synthesis is linked to the disease progression.

Identifiants

pubmed: 38781873
pii: S1043-4666(24)00156-X
doi: 10.1016/j.cyto.2024.156653
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

156653

Informations de copyright

Copyright © 2024. Published by Elsevier Ltd.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Maryam Bourhis (M)

Team of Experimental Oncology and Natural Substances, Cellular and Molecular Immunopharmacology, Laboratory of Agro-industrial and Medical Biotechnology, Faculty of Sciences and Techniques, Sultan Moulay Slimane University, BeniMellal, Morocco.

Abderrazak Idir (A)

Team of Experimental Oncology and Natural Substances, Cellular and Molecular Immunopharmacology, Laboratory of Agro-industrial and Medical Biotechnology, Faculty of Sciences and Techniques, Sultan Moulay Slimane University, BeniMellal, Morocco.

Safa Machraoui (S)

Laboratory of Immunology, Center of Clinical Research, Mohammed VI University Hospital, Faculty of Medicine and Pharmacy, Cadi Ayyad University, Marrakech, Morocco.

Abdelhamid Hachimi (A)

Department of Intensive Care, Mohamed VI University Hospital, Faculty of Medicine and Pharmacy, Cadi Ayyad University, Marrakech, Morocco.

Youssef Elouardi (Y)

Department of Anesthesia and Intensive Care Medicine, Ibn Tofail Hospital, Mohammed VI University Hospital, Faculty of Medicine and Pharmacy, Cadi Ayyad University, Marrakech, Morocco.

Oumayma Jamil (O)

Department of Anesthesia and Intensive Care Medicine, Ibn Tofail Hospital, Mohammed VI University Hospital, Faculty of Medicine and Pharmacy, Cadi Ayyad University, Marrakech, Morocco.

Mohammed Khallouki (M)

Department of Anesthesia and Intensive Care Medicine, Ibn Tofail Hospital, Mohammed VI University Hospital, Faculty of Medicine and Pharmacy, Cadi Ayyad University, Marrakech, Morocco.

Kawtar Zahlane (K)

Laboratory of Medical Analysis, IbnTofail Hospital, Mohammed VI University Hospital, Faculty of Medicine and Pharmacy, Cadi Ayyad University, Marrakech, Morocco.

Morad Guennouni (M)

Science and Technology Team, Higher School of Education and Training, Chouaîb Doukkali University, El Jadida, Morocco.

Raja Hazime (R)

Laboratory of Immunology, Center of Clinical Research, Mohammed VI University Hospital, Faculty of Medicine and Pharmacy, Cadi Ayyad University, Marrakech, Morocco.

Lamiaa Essaadouni (L)

Internal Medicine Department, Mohammed VI University Hospital, Faculty of Medicine and Pharmacy, Cadi Ayyad University, Marrakech, Morocco.

Bouchra Lourhlam (B)

Team of Experimental Oncology and Natural Substances, Cellular and Molecular Immunopharmacology, Laboratory of Agro-industrial and Medical Biotechnology, Faculty of Sciences and Techniques, Sultan Moulay Slimane University, BeniMellal, Morocco.

Moulay Mustapha Ennaji (MM)

Team of Virology, Oncology and Biotechnology, Laboratory of Virology, Oncology, Biosciences, Environment and New Energies, Faculty of Sciences & Technologies Mohammedia, University Hassan II of Casablanca, Casablanca, Morocco.

Hassan Ait Mouse (HA)

Team of Experimental Oncology and Natural Substances, Cellular and Molecular Immunopharmacology, Laboratory of Agro-industrial and Medical Biotechnology, Faculty of Sciences and Techniques, Sultan Moulay Slimane University, BeniMellal, Morocco.

Brahim Admou (B)

Laboratory of Immunology, Center of Clinical Research, Mohammed VI University Hospital, Faculty of Medicine and Pharmacy, Cadi Ayyad University, Marrakech, Morocco.

Abdelmajid Zyad (A)

Team of Experimental Oncology and Natural Substances, Cellular and Molecular Immunopharmacology, Laboratory of Agro-industrial and Medical Biotechnology, Faculty of Sciences and Techniques, Sultan Moulay Slimane University, BeniMellal, Morocco. Electronic address: A.ZYAD@usms.ma.

Classifications MeSH